Publication | Open Access
Treatment Strategy for Rifampin-Susceptible Tuberculosis
142
Citations
15
References
2023
Year
A strategy involving initial treatment with an 8-week bedaquiline-linezolid regimen was noninferior to standard treatment for tuberculosis with respect to clinical outcomes. The strategy was associated with a shorter total duration of treatment and with no evident safety concerns. (Funded by the Singapore National Medical Research Council and others; TRUNCATE-TB ClinicalTrials.gov number, NCT03474198.).
| Year | Citations | |
|---|---|---|
Page 1
Page 1